SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT07526792 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

406

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: SYS6002
DRUG: Investigator's Choice of Chemotherapy

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.